{"id":452678,"date":"2021-03-08T09:03:23","date_gmt":"2021-03-08T14:03:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452678"},"modified":"2021-03-08T09:03:23","modified_gmt":"2021-03-08T14:03:23","slug":"inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/","title":{"rendered":"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LA JOLLA, Calif, March  08, 2021  (GLOBE NEWSWIRE) &#8212; INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d or \u201cINmune\u201d), a clinical-stage immunology company focused on\u00a0developing treatments that harness a patient\u2019s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021.<\/p>\n<p>\n        <b>33<sup>rd<\/sup> Annual Roth Virtual Conference<\/b><br \/>\n        <br \/>Panel Discussion: Therapeutics Against SARS-CoV-2 \u2013 Viral Variants Will Not Fade Away<br \/>Panel Date: Monday, March 15, 2021<br \/> Panel Time: 12:00 PM Eastern Time<br \/>Interested parties may register for the panel <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7bENfqCKmaF26A3nD5mN9mkfGS6e8Ng-j8xdJsqIfP0X7GrvRrcTtu7X47FbLfpZMlTJS5iM6Ms35WMQZ-1msSzpaAU-v_PFqqu68lFUkYVGm77yyEs1HCKov9RwYC_mQCJvZ9fhrQgSFHgss0h4-1x0Z1ca6A7RWNXyeWyH_WYDBlblFkCFxgQUXW7RY2im\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>here<\/u><\/a><\/p>\n<p>\n        <b>Oppenheimer 31<sup>st<\/sup> Annual Healthcare Conference<\/b><br \/>\n        <br \/>Presentation Date: Tuesday, March 16, 2021<br \/>Presentation Time: 1:10 PM Eastern Time<br \/>Interested parties may register for the panel <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q9C1ECpT9DHTk8MGEvmRazxSi4AuMX4Ar-dLCa6QygdrMYGHDnAVP2yxWqifiZpeD_03wFDN_Q6SoOPwnWrENdmf-DnvoJLEZ_FfIo4tnpM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>here<\/u><\/a><\/p>\n<p>Please contact your representative at either Roth or Oppenheimer to schedule a virtual one-on-one meeting with INmune Bio during the respective conference. <\/p>\n<p>\n        <b>About INmune Bio, Inc.<\/b><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0EHX4AwLYDumfAHSA8HxPhgn3VWxDCn-9QXUWxDFqWrNZzN-WIf1lkYl4lzN5vvw8KNVGzTjZqpYGmmBW3-dFlyfT143vc6PT1rScc9i4u5aU7aKwfOAzKufFabHWedimhW_skvDSvvJrQkZxYNoMTg3ktihHx2juRidsiYw4DFnAiYMWokzxqqyulzro-uZ2Ir2kw3Wu2ajrLJ4cTIzBFq4pv-HWdXKSwAw5vIPP-dfghbL10tgiGc8Hj7v-2s7\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>INmune Bio, Inc<\/u><br \/>\n        <\/a>. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor\u2122), cancer (INB03\u2122), Alzheimer\u2019s (XPro595), and NASH (LIVNate\u2122). The Natural Killer Cell Priming Platform includes INKmune\u2122 aimed at priming the patient\u2019s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio\u2019s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S6NfTjo7gOA3uwpYuWqqn46f63CceoC9Iob-o45vT_6RHxZxl6h_azS2pB5PcvvehW22HerbAGPy4HTcqXPObYZvHY1-9ub5G6ywMUi6AV0jXNGwBfkdi9MeAZDTL61LehEhzCLQt6hpgqa910WJzAoAy32VOIkrC8QJeVgfAMhNLBcNesNG9wTo7Vmw-NZpjRsUFk4-XMlfb7epkfeL8zRnv5D8KpW7wthrHO4K5Aw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.inmunebio.com<\/u><\/a>.<\/p>\n<p>\n        <b>Information\u00a0about Forward-Looking Statements<\/b><br \/>\n        <br \/>Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.\u00a0 Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03\u2122, Quellor\u2122, XPro1595, LIVNate\u2122, and INKmune\u2122 are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.<\/p>\n<p>\n        <b>INmune Bio Contact:<\/b><br \/>\n        <br \/>David Moss, CFO<br \/> (858) 964-3720<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rbFokYEwD-bnKeTYhUqs3888H_U5VyCXhchKt4XM-y_4wneo9M_-Jq3w-f-s4ha8fco9SVHRA4aT9bQhhb8Z1_jn_MhbzCpaQXZS9YOLzsw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>DMoss@INmuneBio.com<\/u><\/a><\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>Chuck Padala <br \/>LifeSci Advisors, LLC<br \/>(917) 741-7792<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=am6GxShFKmF8Uu7TVLnvb4oE2DbC0CWIc9VjSDR0C6sxmj4MoVyh41aHkpBe2MKkram5qW80Mep0nnIuSXn5o2x1V6pxW5gK_X9mKtLlhes=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Chuck@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/fd4e570b-e82f-4748-8ba9-cd0adf7ee63f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) &#8212; INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d or \u201cINmune\u201d), a clinical-stage immunology company focused on\u00a0developing treatments that harness a patient\u2019s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021. 33rd Annual Roth Virtual Conference Panel Discussion: Therapeutics Against SARS-CoV-2 \u2013 Viral Variants Will Not Fade AwayPanel Date: Monday, March 15, 2021 Panel Time: 12:00 PM Eastern TimeInterested parties may register for the panel here Oppenheimer 31st Annual Healthcare Conference Presentation Date: Tuesday, March 16, 2021Presentation Time: 1:10 PM Eastern TimeInterested parties may register for the panel here Please contact your representative at either Roth or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452678","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) &#8212; INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d or \u201cINmune\u201d), a clinical-stage immunology company focused on\u00a0developing treatments that harness a patient\u2019s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021. 33rd Annual Roth Virtual Conference Panel Discussion: Therapeutics Against SARS-CoV-2 \u2013 Viral Variants Will Not Fade AwayPanel Date: Monday, March 15, 2021 Panel Time: 12:00 PM Eastern TimeInterested parties may register for the panel here Oppenheimer 31st Annual Healthcare Conference Presentation Date: Tuesday, March 16, 2021Presentation Time: 1:10 PM Eastern TimeInterested parties may register for the panel here Please contact your representative at either Roth or &hellip; Continue reading &quot;INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T14:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021\",\"datePublished\":\"2021-03-08T14:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/\"},\"wordCount\":618,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/\",\"name\":\"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==\",\"datePublished\":\"2021-03-08T14:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/","og_locale":"en_US","og_type":"article","og_title":"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - Market Newsdesk","og_description":"LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) &#8212; INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d or \u201cINmune\u201d), a clinical-stage immunology company focused on\u00a0developing treatments that harness a patient\u2019s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021. 33rd Annual Roth Virtual Conference Panel Discussion: Therapeutics Against SARS-CoV-2 \u2013 Viral Variants Will Not Fade AwayPanel Date: Monday, March 15, 2021 Panel Time: 12:00 PM Eastern TimeInterested parties may register for the panel here Oppenheimer 31st Annual Healthcare Conference Presentation Date: Tuesday, March 16, 2021Presentation Time: 1:10 PM Eastern TimeInterested parties may register for the panel here Please contact your representative at either Roth or &hellip; Continue reading \"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T14:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021","datePublished":"2021-03-08T14:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/"},"wordCount":618,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/","name":"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==","datePublished":"2021-03-08T14:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDM5OSM0MDQ4NDA4IzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452678"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452678\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}